# Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)

> **NCT00122876** · PHASE1,PHASE2 · COMPLETED · sponsor: **Light Sciences Oncology** · enrollment: 25 (—)

## Conditions studied

- Carcinoma, Hepatocellular
- Liver Neoplasms

## Interventions

- **PROCEDURE:** Photodynamic therapy
- **DRUG:** Talaporfin Sodium

## Key facts

- **NCT ID:** NCT00122876
- **Lead sponsor:** Light Sciences Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 25 (—)
- **Last updated:** 2007-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122876, "Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00122876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*